2017-08-15
希弗全参展2017丝路肾脏病论坛暨国际肾脏病学会区域培训中心会议

      2017.8.8-8.10,由刘志红院士(ISN国际肾脏病学会理事)牵头、侯凡凡院士联合参与,南京总医院-国家肾脏疾病临床研究中心和新疆医科大学第一附属医院联合主办了2017丝路肾脏病论坛暨国际肾脏病学会区域培训中心会议。希弗全作为血透抗凝治疗的重要临床用药应邀参展。大会同时邀请了知名学者ISN国际肾脏病学会前主席John Feehally教授,美国布朗大学肾内科主任Douglas Shemin教授,以及巴基斯坦、塔吉克斯坦等“一带一路”重要区域节点的专家学者作精彩学术分享。会议期间新疆医科大学第一附属医院与南京总医院、美国布朗大学签约组建“姐妹肾病研究中心”,通过交流学习、培训等方式,让新疆肾病医疗水平与国际接轨。会后专家们主动参观希弗全展台并就希弗全的临床应用展开了热烈讨论,通过产品介绍和DA资料传递,医生们对希弗全的治疗特点有了进一步了解,非常希望在临床诊疗中积极使用这一原研进口产品,同时中国先锋医药控股有限公司也将继续致力于积极推动希弗全这一优质产品更好的服务新疆医疗。


    During 8-10 August, 2017, the 2017 Silk Road Forum of Kidney Disease and the International Society of Nephrology Regional Training Center Conference , which was led by Ms. Liu Zhihong academician (ISN International Society of Nephrology), and jointly participated by Ms. Hou Fan Fan academician , was co-organised by Nanjing General Hospital - National Kidney Disease Clinical Research Center and the First Affiliated Hospital of Xinjiang Medical University. As an important clinically therapy drug of hemodialysis anticoagulation,Fluxum was invited to the conference. The former Chairman of ISN, Prof. John Feehally and Prof. Douglas Shemin, who is Director of Department of Nephrology of Brown University, USA, and experts and scholars from important regional nodes of "Belt and Road" such as Pakistan and Tajikistan, were also invited to the conference to share their academic ideas. During the meeting, the First Affiliated Hospital of Xinjiang Medical University and the Nanjing General Hospital, and Brown University, USA signed the agreement for building "Sister Kidney Disease Research Center", through the exchange of learning, training, etc., in order to improve the medical treatment of kidney disease in Xinjiang to the international level. The experts took the initiative to visit the exhibition stand and started a lively discussion about clinical application of Fluxum after the meeting. Through the detailed introduction of the product and display advertising,the doctors had a further understanding of the treatment characteristics of Fluxum. They do hope to use the imported originator in clinical diagnosis and treatment,meanwhile China Pioneer Pharma Holdings Co., Ltd. will also continue to promote the better service of this high-quality product for Xinjiang medical treatment.


AW杨悦文报道